Skip to main content
OpenTrials
Completed

NCT Number: NCT00882661

SECURE®-C Cervical Artificial Disc Clinical Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study

The purpose of the pivotal IDE clinical study was to evaluate the safety and effectiveness of the SECURE®-C Cervical Artificial Disc for the treatment of symptomatic cervical disc disease at one level between C3 and C7, compared to anterior cervical discectomy and fusion.

The purpose of the Postmarket Approval Study is to evaluate the long-term safety and efficacy associated with the use of the SECURE-C Cervical Artificial Disc

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Ages Eligible for Study: 18 to 60 years

Genders Eligible for Study: Both

Accepts Healthy Volunteers: No

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Symptomatic cervical disc disease (SCDD) in one vertebral level between C3-C7, defined as neck or arm (radicular) pain, or functional or neurological deficit and radiographic confirmation (by CT, MRI, X-ray, etc.) of any of the following:
  • Herniated nucleus pulposus;
  • Radiculopathy or myelopathy;
  • Spondylosis (defined by the presence of osteophytes); or
  • Loss of disc height.
  • Age between 18 and 60 years
  • Failed at least 6 weeks of conservative treatment
  • Neck Disability Index (NDI) Questionnaire score of at least 30 (as percentage of 50 point total)
  • Able to understand and sign informed consent form
  • Psychosocially, mentally and physically able to fully comply with this protocol including adhering to follow-up schedule and filling out forms
  • Able to meet the proposed follow-up schedule at 6 weeks, 3 months, 6 months, 12 months and 24 months
  • Able to follow postoperative management program

Exclusion criteria

  • More than one vertebral level requiring treatment
  • Prior fusion surgery adjacent to the vertebral level being treated
  • Prior surgery at the level to be treated
  • Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma
  • Radiographic confirmation of facet joint disease or degeneration, defined as apparent sclerosis and/or hypertrophy of the facets demonstrated on AP radiographs as a disruption of the normally smooth facet curve
  • Marked cervical instability on resting lateral or flexion/extension radiographs:
  • Translation greater than 3mm, and/or
  • More than 11° of rotational difference from that of either adjacent level.
  • Severe spondylosis at the level to be treated as characterized by any of the following:
  • Bridging osteophytes;
  • A loss of disc height greater than 50%; or
  • Absence of motion (<2°)
  • Neck or arm pain of unknown etiology
  • Osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease
  • Pregnant or interested in becoming pregnant in the next 2 years
  • Active systemic or local infection
  • Known allergy to titanium, polyethylene, cobalt, chromium or molybdenum
  • Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids)
  • Rheumatoid arthritis or other autoimmune disease
  • Systemic disease including AIDS, HIV, Hepatitis
  • Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there has been no clinical signs or symptoms of the malignancy for at least 5 years
  • Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis, etc.
  • Acute mental illness or substance abuse
  • Use of bone growth stimulator within past 30 days
  • Participation in other investigational device or drug clinical trials within 30 days of surgery
  • Prisoners

Treatment and study plan

SECURE-C Cervical Artificial Disc

Device

Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc

ASSURE Cervical plate and an allograft interbody spacer

Device

Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion

Primary outcomes

  1. Individual Patient Overall Success

    Time frame: 24 months

    Individual patient overall success defined as pain/disability improvement of at least 25% in Neck Disability Index (NDI) compared to baseline; no device failures requiring revision, removal, reoperation, or supplemental fixation; absence of major complications defined as major vessel injury, neurological damage, or nerve injury; and for control fusion patients only, radiographic fusion

Secondary outcomes

  1. Neck Disability Index (NDI)

    Time frame: 24 months

    Neck Disability Index (NDI) success defined as ≥25% improvement at 24 months from baseline

  2. Neck Pain Visual Analog Scale (VAS)

    Time frame: 24 months

    Improvement of 20mm from baseline in neck pain measured using the Visual Analog Scale (VAS)

  3. Left Arm Pain Visual Analog Scale (VAS)

    Time frame: 24 months

    Improvement of 20mm from baseline in left arm pain measured using the Visual Analog Scale (VAS)

  4. Right Arm Pain Visual Analog Scale (VAS)

    Time frame: 24 months

    Improvement of 20mm from baseline in right arm pain measured using the Visual Analog Scale (VAS)

  5. SF-36 PCS

    Time frame: 24 months

    Health Status Survey SF-36 physical composite scores: 15% improvement from baseline

  6. SF-36 MCS

    Time frame: 24 months

    Health Status Survey SF-36 mental composite scores: 15% improvement from baseline

  7. Satisfaction

    Time frame: 24 months

    Patient satisfaction (definitely/mostly): proportion of patients

Sponsors and collaborators

Lead sponsor

Globus Medical Inc

Industry

Registry information

Official study title

A Prospective Randomized Clinical Investigation of the SECURE-C Cervical Artificial Disc: A Pivotal Study/ SECURE-C Cervical Artificial Disc Postmarket Approval Study

Important dates

Study start
2005
Primary completion
2010
Study completion
2017
First posted
Apr 16, 2009
Registry last updated
Jun 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.